Stability of an extemporaneous oral liquid aprepitant formulation

Supportive Care in Cancer

Volumn 17, Issue 6, 2009, Pages 701-706

  Dupuis, L Lee ^a,c   Lingertat Walsh, Karen ^b   Walker, Scott E ^c,d  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Aprepitant; Compounding; Suspension

Indexed keywords

APREPITANT;

ARTICLE; CHROMATOGRAPHY; DRUG DEGRADATION; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANTIEMETICS; CHEMISTRY, PHARMACEUTICAL; CHILD; DRUG COMPOUNDING; DRUG PACKAGING; DRUG STABILITY; DRUG STORAGE; GLASS; HUMANS; MORPHOLINES; PHARMACEUTICAL SOLUTIONS; POLYETHYLENE TEREPHTHALATES; TEMPERATURE; TIME FACTORS; VEHICLES;

EID: 67349200267     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-008-0539-5     Document Type: Article

References (13)

1. A Coates S Abraham SB Kaye 1983 On the receiving end-patients' perception of the side-effects of cancer chemotherapy Eur J Cancer Clin Oncol 19 203 208 (Pubitemid 13155858)
2. M De Boer-Dennert R de Wit PIM Schmitz 1997 Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists Br J Cancer 76 1055 1061 (Pubitemid 27434663)
3. AM Griffin PN Butow AS Coates 1996 On the receiving end V: patient perceptions of the side effects of chemotherapy in 1993 Ann Oncol 7 189 195 (Pubitemid 26094884)
4. American Society of Health-System Pharmacists 1999 ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery Am J Health Syst Pharm 56 729 764 (Pubitemid 29197511)
5. F Roila A Del Favero RJ Gralla 1998 Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the Perugia Consensus Conference Ann Oncol 9 811 819 (Pubitemid 28440438)
6. RJ Gralla D Osoba MG Kris 1999 Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines J Clin Oncol 17 2971 2994 (Pubitemid 29415258)
7. MG Kris PJ Hesketh J Herrstedt 2005 Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy Support Care Cancer 13 85 96 (Pubitemid 40558163)
8. PJ Hesketh SM Grunberg RJ Gralla 2003 The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multi-national, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group J Clin Oncol 21 4112 4119 (Pubitemid 46606178)
9. S Poli-Bigelli J Rodrigues-Pereira AD Carides 2003 Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America Cancer 97 3090 3098 (Pubitemid 36676265)
10. AR Martin AD Carides JD Pearson 2003 Functional relevance of antiemetic control: experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant Eur J Cancer 39 1395 1401 (Pubitemid 36773782)
11. LA Trissel 1983 Avoiding common flaws in stability and compatibility studies of injectable drugs Am J Hosp Pharm 40 1159 1160
12. LA Trissel 1988 Stability studies: five years later Am J Hosp Pharm 45 1569 1571
13. I Olver S Shelukar K Thompson 2007 Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant Int J Nanomedicine 2 13 18 (Pubitemid 46901776)